Publications by authors named "Ammayappan Radhakrishnan"
Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis.
Agibothu Kupparam Hemanth Kumar Abhijit Kadam Ramesh Karunaianantham Manoharan Tamizhselvan Chandrasekaran Padmapriyadarsini Ammayappan Radhakrishnan
Ther Drug Monit
June 2024
Article Synopsis
- The study aimed to investigate how metformin affects the plasma levels of tuberculosis drugs (rifampicin, isoniazid, and pyrazinamide) in patients undergoing standard antituberculosis treatment (ATT) and the role of specific gene polymorphisms on drug metabolism.
- In a phase IIB clinical trial, non-diabetic adults with pulmonary tuberculosis were divided into two groups: one receiving standard ATT and the other receiving ATT plus metformin; pharmacokinetic measurements were taken to assess drug levels.
- Results indicated that metformin increased the clearance of rifampicin, isoniazid, and pyrazinamide, particularly in patients with certain genetic variants, though it had minimal impact on treatment
4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Banurekha Velayutham Mohideen Shaheed Jawahar Dina Nair Pooranagangadevi Navaneethapandian Chinnaiyan Ponnuraja Ammayappan Radhakrishnan
Trop Med Int Health
April 2020
Background: Shortening tuberculosis (TB) treatment duration is a research priority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India.
Methods: New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month moxifloxacin regimens [moxifloxacin (M), isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)] or to a control regimen (2H R Z E /4R H ) [C].